Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
1,046
mentions
- News 657
- X 288
- Blogs 46
- Facebook 36
- +3 more
